TITLE

ALS awareness.Coganeâ„¢ Gets Orphan Drug Status

PUB. DATE
November 2011
SOURCE
PN;Nov2011, Vol. 65 Issue 11, p21
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Phytopharm PLC drug Coganeâ„¢ was granted the orphan drug status for use in the treatment of amyotrophic lateral sclerosis (ALS) from the U.S. Food and Drug Administration (FDA).
ACCESSION #
66733264

 

Related Articles

  • New Gene Mutation Discovered.  // PN;Jun2009, Vol. 63 Issue 6, p32 

    The article highlights the discovery of the gene ALS6 by a consortium of scientists funded by the ALS Association (ALSA) in the U.S. The research shows that ALS6 is 5% responsible for cases of inherited amyotrophic lateral sclerosis (ALS). The researchers indicate that the discovery will lead to...

  • Bucket Benefits.  // PN;Nov2015, Vol. 69 Issue 11, p40 

    The article presents information on the research announced by the American nonprofit organization, ALS Association on amyotrophic lateral sclerosis (ALS) which is made possible by the ALS Ice Bucket Challenge. The guidance would be submitted to the Food and Drug Administration (FDA) and the...

  • Chapter 16: Clinical Trials in Amyotrophic Lateral Sclerosis. Kaufmann, Petra // Amyotrophic Lateral Sclerosis: A Guide for Patients & Families;2009, p255 

    Chapter 16 of the book "Amyotrophic Lateral Sclerosis: A Guide for Patients and Families," Third Edition, is presented. This chapter deals with issues related to clinical trials of a tentative drug for amyotrophic lateral sclerosis. The importance of clinical trials, the use of placebo controls...

  • ALS Drug Development: Reflections from the Past and a Way Forward Aggarwal, Swati; Cudkowicz, Merit // Neurotherapeutics;Oct2008, Vol. 5 Issue 4, p516 

    Summary: Tremendous advances in our understanding of pathogenesis of amyotrophic lateral sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique compounds have been tested. Nevertheless, riluzole is currently the only treatment that prolongs survival. We...

  • Cellceutix Targeting Head and Neck Cancer with Lead Drug. Boggs, Jennifer // BioWorld Today;6/26/2008, Vol. 19 Issue 124, p1 

    The article focuses on the development efforts of Cellceutix Pharmaceutical Inc. to produce innovative drugs for oncology and inflammatory diseases. A promising drug reportedly developed by this company is called Kevetrin which is said to have resulted to a tumor reduction after its...

  • Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets. Bosco, Daryl A.; Landers, John E. // CNS & Neurological Disorders - Drug Targets;Dec2010, Vol. 9 Issue 6, p779 

    Amyotrophic lateral sclerosis (ALS) is an incurable disease resulting from the deterioration of motor neurons. The onset of disease typically occurs in the fifth decade of life and progresses rapidly; death occurs for 75% of patients within 5 years. The only drug that is available to treat ALS...

  • Financings Roundup.  // BioWorld Today;8/25/2009, Vol. 20 Issue 163, p11 

    The article reports on a private investment from ACCBT Corp. and grant from the Israeli Office of the Chief Scientist received by BrainStorm Cell Therapeutics Inc. The funding will allow BrainStorm Cell Therapeutics to complete preclinical studies of a treatment for amyotrophic lateral...

  • Validation of UV Spectrophotometric Method for Determination of Riluzole in Pharmaceutical Dosage Form. Saminathan, J.; Vetrichelvan, T. // International Journal of ChemTech Research;Apr-Jun2011, Vol. 3 Issue 2, p560 

    A simple and reproducible method was developed for the assay of riluzole in tablets. The excipients in the commercial tablet preparation did not interfere with the assay. Various methods for analysis of the same are available but are time consuming and expensive. Here we have developed a new,...

  • Financings Roundup.  // BioWorld Today;4/23/2008, Vol. 19 Issue 79, p2 

    The article provides information on Cambria Pharmaceuticals Inc. and the $5.4 million Series A round it closed with participating investors. The funds will reportedly be used for the advancement of the company's lead program in amyotrophic lateral sclerosis and to support drug discovery efforts...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics